Gomez F, Bogas G, Gonzalez M, Campo P, Salas M, Diaz-Perales A, Rodriguez M J, Prieto A, Barber D, Blanca M, Torres M J, Mayorga C
Allergy Unit, IBIMA-Regional University Hospital of Malaga, UMA, Spain.
Research Laboratory, IBIMA-Regional University Hospital of Malaga, UMA, Malaga, Spain.
Clin Exp Allergy. 2017 Mar;47(3):339-350. doi: 10.1111/cea.12901.
The peach non-specific lipid transfer protein, Pru p 3, is the primary sensitizer in fruits and responsible for severe reactions in the Mediterranean area. Peach allergy is frequently associated with other allergies such as peanut. Therefore, it is important to assess how specific immunotherapy to Pru p 3 could affect both peach and peanut tolerance.
To evaluate peach and peanut desensitization and immunological changes after 1 year of Pru p 3 sublingual immunotherapy (SLIT) in patients with systemic allergic reactions to peach and/or peanut.
Forty-eight peach allergic patients, 36 treated with SLIT and 12 non-treated, were monitored for 12 months. Treated patients were subclassified as peanut allergic (Group A), sensitized (Group B) or tolerant (Group C). SLIT effect was evaluated by skin prick test (SPT) reactivity and food challenge. Immunological changes were evaluated by monitoring sIgE and sIgG4 levels and basophil reactivity.
After 1 year of SLIT, the weal area in SPT significantly decreased and a significant increase in peach threshold in treated patients was observed (P < 0.001). Patients in Group A showed a significant decrease in peanut SPT weal area and an increase in peanut threshold (P < 0.001). Immunological changes were observed in treated patients only, with a significant decrease in sIgE and a parallel increase in sIgG4, sIgG4/sIgE and basophil reactivity for both Pru p 3 and Ara h 9.
After 1 year, Pru p 3 SLIT induces both desensitization and immunological changes not only for peach but also for other food allergens relevant in the induction of severe reactions such as peanut.
桃非特异性脂质转移蛋白Pru p 3是水果中的主要致敏原,在地中海地区会引发严重反应。桃过敏常与其他过敏症相关,如花生过敏。因此,评估针对Pru p 3的特异性免疫疗法如何影响对桃和花生的耐受性很重要。
评估对桃和/或花生发生全身过敏反应的患者接受1年Pru p 3舌下免疫疗法(SLIT)后的桃和花生脱敏情况及免疫变化。
对48例桃过敏患者进行了12个月的监测,其中36例接受SLIT治疗,12例未接受治疗。接受治疗的患者被分为花生过敏组(A组)、致敏组(B组)或耐受组(C组)。通过皮肤点刺试验(SPT)反应性和食物激发试验评估SLIT的效果。通过监测sIgE和sIgG4水平以及嗜碱性粒细胞反应性评估免疫变化。
SLIT治疗1年后,治疗患者的SPT风团面积显著减小,桃阈值显著升高(P < 0.001)。A组患者的花生SPT风团面积显著减小,花生阈值升高(P < 0.001)。仅在接受治疗的患者中观察到免疫变化,Pru p 3和Ara h 9的sIgE显著降低,sIgG4、sIgG4/sIgE和嗜碱性粒细胞反应性同时升高。
1年后,Pru p 3 SLIT不仅能诱导对桃的脱敏和免疫变化,还能诱导对其他与严重反应诱导相关的食物过敏原(如花生)的脱敏和免疫变化。